PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15246972-2 2004 Exposure of human umbilical vein endothelial cells to forskolin or dibutyryl cAMP, which increase intracellular cAMP by separate mechanisms, inhibited the thrombin-induced ICAM-1 expression. Colforsin 54-63 coagulation factor II, thrombin Homo sapiens 155-163 16055445-2 2005 Elevation of cAMP and maximal cAMP-dependent protein kinase activation induced by 10 microm forskolin, 40 microm 3-isobutyl-1-methylxanthine caused a 50% reduction in myosin II regulatory light chain (RLC) phosphorylation and a 35% drop in isometric tension, but it did not inhibit thrombin-stimulated increases in RLC phosphorylation and isometric tension. Colforsin 92-101 coagulation factor II, thrombin Homo sapiens 282-290 15886804-10 2005 Elevating cAMP levels with PGI(2) or forskolin precludes thrombin-induced p27 and p31 tyrosine phosphorylation. Colforsin 37-46 coagulation factor II, thrombin Homo sapiens 57-65 15543559-3 2005 Forskolin, a direct activator of adenylyl cyclase, reduced the thrombin-induced p38 MAP kinase phosphorylation, and significantly suppressed the thrombin-stimulated accumulation of HSP27. Colforsin 0-9 coagulation factor II, thrombin Homo sapiens 145-153 17704206-5 2007 When cAMP synthesis was slightly elevated with a submaximal concentration of 7-deacetyl-7-(O-[N-methylpiperazino]-gamma-butyryl)-dihydrochloride-forskolin (MPB-forskolin), we found that low doses of either atrial natriuretic peptide (ANP) or NO donors potentiated the inhibitory effects of MPB-forskolin on thrombin-induced permeability. Colforsin 145-154 coagulation factor II, thrombin Homo sapiens 307-315 17472573-5 2007 Secretion in response to thrombin, a protease-activated receptor-1 agonist peptide, histamine, forskolin and adrenaline (epinephrine) was inhibited. Colforsin 95-104 coagulation factor II, thrombin Homo sapiens 25-33 15543559-3 2005 Forskolin, a direct activator of adenylyl cyclase, reduced the thrombin-induced p38 MAP kinase phosphorylation, and significantly suppressed the thrombin-stimulated accumulation of HSP27. Colforsin 0-9 coagulation factor II, thrombin Homo sapiens 63-71 15246972-7 2004 We observed that treating cells with forskolin blocked the activation of p38 MAPK, and inhibition of p38 MAPK interfered with phosphorylation of RelA/p65 induced by thrombin. Colforsin 37-46 coagulation factor II, thrombin Homo sapiens 165-173 11323002-8 2001 Cilostazol inhibited completely thrombin-induced aggregation in the presence of 1 microM forskolin, when cAMP levels were two-fold higher than those in the absence of forskolin. Colforsin 89-98 coagulation factor II, thrombin Homo sapiens 32-40 12609843-5 2003 In comparison, Gi-mediated signaling induced by either thrombin, ADP, or adrenaline, examined by suppression of forskolin-stimulated rise in cyclic AMP (cAMP) was impaired, indicating dysfunctional Galphai signaling. Colforsin 112-121 coagulation factor II, thrombin Homo sapiens 55-63 12588708-6 2003 Pretreatment of HMEC with 10 micro M forskolin plus 1 micro M IBMX (FI) to elevate intracellular cAMP levels inhibited both thrombin-induced RhoA activation and translocation responses. Colforsin 37-46 coagulation factor II, thrombin Homo sapiens 124-132 12574812-4 2003 Pretreatment of thrombin-stimulated platelets with forskolin resulted in a concentration- dependent inhibition of P-selectin expression that correlated with adenylyl cyclase activity. Colforsin 51-60 coagulation factor II, thrombin Homo sapiens 16-24 9539153-4 1998 The stable PGI2 analog iloprost, like other cAMP-raising agents (forskolin and adenosine), caused an acute dose-dependent increase in vWf release and potentiated the secretory response to thrombin. Colforsin 65-74 coagulation factor II, thrombin Homo sapiens 188-196 10484345-4 1999 Treatment with 0.5 microM thrombin increased transendothelial albumin clearance rate (0.012 +/- 0.003 and 0.035 +/- 0.005 microl/min for control and thrombin, respectively); the increase was prevented with forskolin + 3-isobutyl-1-methylxanthine (F + I) treatment. Colforsin 206-215 coagulation factor II, thrombin Homo sapiens 26-34 9609742-1 1998 Exposure of cultured human umbilical vein endothelial cells to the cAMP agonists theophylline and forskolin decreased constitutive isometric tension of a confluent monolayer inoculated on a collagen membrane, but it did not prevent increased tension in cells exposed to thrombin. Colforsin 98-107 coagulation factor II, thrombin Homo sapiens 270-278 8954139-3 1996 Addition of a thromboxane (TX)A2 mimetic (U46619 or STA2) or thrombin stimulated the formation of inositol phosphates and dose-dependently augmented a prostaglandin (PG)I2 mimetic (iloprost)- or forskolin-induced cAMP formation. Colforsin 195-204 coagulation factor II, thrombin Homo sapiens 61-69 8954139-6 1996 The elevation of [Ca2+]i induced by thrombin, STA2 or PGE2 was significantly suppressed by pretreatment of the cells with TPA (100 nM) as well as cAMP mimetics such as dibutyryl cAMP (5 mM), forskolin (5 microM) and iloprost (1 microM). Colforsin 191-200 coagulation factor II, thrombin Homo sapiens 36-44 8702835-3 1996 This report examines the role of ERKs and Jun N-terminal kinase 1 (JNK1) groups of mitogen-activated protein kinases in thrombin-induced DNA synthesis in VSMCs using agents such as forskolin and dibutyrylcyclic AMP that increase intracellular cAMP levels. Colforsin 181-190 coagulation factor II, thrombin Homo sapiens 120-128 8702835-7 1996 In contrast to ERKs and c-Fos, thrombin-induced JNK1 activation and c-Jun expression were sensitive to inhibition by forskolin, suggesting an association of these events with thrombin-stimulated growth in these cells. Colforsin 117-126 coagulation factor II, thrombin Homo sapiens 31-39 8702835-7 1996 In contrast to ERKs and c-Fos, thrombin-induced JNK1 activation and c-Jun expression were sensitive to inhibition by forskolin, suggesting an association of these events with thrombin-stimulated growth in these cells. Colforsin 117-126 coagulation factor II, thrombin Homo sapiens 175-183 8702835-8 1996 Thrombin also increased AP-1 activity, and this response was significantly blunted by forskolin. Colforsin 86-95 coagulation factor II, thrombin Homo sapiens 0-8 8880128-7 1996 In contrast, the results from HUVEC and HAVEC differed significantly, not only in magnitude but also in direction, when the cells were exposed to forskolin coincubated with PMA, LPS or thrombin, and in magnitude alone when exposed to LPS only. Colforsin 146-155 coagulation factor II, thrombin Homo sapiens 185-193 8621441-7 1996 Endothelin- or thrombin-induced activation of mitogen-activated protein kinases was significantly inhibited by activation of cyclic AMP-dependent protein kinase by forskolin. Colforsin 164-173 coagulation factor II, thrombin Homo sapiens 15-23 1375452-4 1992 However, we report here that while signal transduction induced by ADP plus a thromboxane mimetic (U46619), or by thrombin, is inhibited by stimulators of adenylate cyclase such as a prostaglandin I2 (PGI2) analogue (Iloprost), PGD2 and forskolin, elevation of cyclic AMP does not inhibit either platelet adhesion to collagen or the associated Ca2+ mobilization, phosphatidic acid formation or 5-hydroxytryptamine secretion. Colforsin 236-245 coagulation factor II, thrombin Homo sapiens 113-121 7842460-8 1994 These differences were associated with inhibited aggregatory responses to thrombin (for forskolin treated platelets) and the thromboxane mimetic U44069 (for GR 32191B treated platelets). Colforsin 88-97 coagulation factor II, thrombin Homo sapiens 74-82 7903872-7 1994 An increase of cAMP upon the addition of forskolin reduced the permeability in all endothelial cell strains under basal conditions and after exposure to thrombin. Colforsin 41-50 coagulation factor II, thrombin Homo sapiens 153-161 1333990-5 1992 SMC treatment with pertussis toxin and forskolin indicated that the mitogenic activity of thrombin may be induced via signal transduction mechanism(s) involving changes in cAMP levels and activation of a Gi-like protein. Colforsin 39-48 coagulation factor II, thrombin Homo sapiens 90-98 1331412-4 1992 Thrombin, although ineffective alone, also potentiated cyclic AMP production stimulated by vasoactive intestinal peptide (1.6 +/- 0.2-fold), cholera toxin (3.0 +/- 0.6-fold) and AIF4- (2.3 +/- 0.6-fold), but not by forskolin (0.9 +/- 0.1-fold). Colforsin 215-224 coagulation factor II, thrombin Homo sapiens 0-8 1309828-8 1992 In addition, the inhibitory effect of thrombin on MEG-01 cell growth was mimicked by cAMP level enhancing agents such as forskolin, prostaglandin E1 and Bt2cAMP. Colforsin 121-130 coagulation factor II, thrombin Homo sapiens 38-46 1651428-9 1991 Although forskolin-induced in cAMP caused a marked prevention of inositol 1, 4, 5-trisphosphate (IP3) production stimulated with thrombin, 8-bromo cGMP and EDRF-induced increase in cGMP had no effect of IP3 production. Colforsin 9-18 coagulation factor II, thrombin Homo sapiens 129-137 1710933-7 1991 Forskolin and iloprost, two agents that increase the level of cellular cAMP in EC, are very effective in inhibiting thrombin-evoked cytosolic Ca2+ rise, acetyltransferase activation and PAF production; this suggests that endogenously generated prostacyclin (PGI2) may modulate the synthesis of PAF in human endothelial cells. Colforsin 0-9 coagulation factor II, thrombin Homo sapiens 116-124 2475104-3 1989 Iloprost (a stable analog of PGI2) and forskolin each completely inhibited platelet aggregation by 2 nM thrombin and markedly decreased cleavage of aggregin. Colforsin 39-48 coagulation factor II, thrombin Homo sapiens 104-112 14517385-9 1998 The transduction mechanism involved in this action of thrombin seems to be via cAMP, since forskolin or the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine restored the ability of HUVECs that had been exposed to thrombin to adhere. Colforsin 91-100 coagulation factor II, thrombin Homo sapiens 54-62 14517385-9 1998 The transduction mechanism involved in this action of thrombin seems to be via cAMP, since forskolin or the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine restored the ability of HUVECs that had been exposed to thrombin to adhere. Colforsin 91-100 coagulation factor II, thrombin Homo sapiens 221-229 9795233-4 1998 The thrombin-induced (0.1 U/ml) increase in production of [32P]PA, "overshoots" in [32P]PIP and [32P]PIP2 ([32P]phosphatidylinositol 4,5-bisphosphate), and the increase in [32P]PI and secretion of ADP+ATP were abolished by forskolin (10-7 M). Colforsin 223-232 coagulation factor II, thrombin Homo sapiens 4-12 3040721-8 1987 Forskolin, a direct activator of adenylate cyclase, also blocked induction of c-sis mRNA by thrombin and TGF-beta and inhibited the release of PDGF activity into the media of these cells. Colforsin 0-9 coagulation factor II, thrombin Homo sapiens 92-100 3372537-6 1988 Pretreatment of cultures with 50 microM forskolin, a potent activator of adenylyl cyclase, completely blocked B chain transcription by thrombin and TGF-beta, but did not inhibit A chain transcription induced by TGF-beta. Colforsin 40-49 coagulation factor II, thrombin Homo sapiens 135-143 2410292-2 1985 In the presence of 10 microM isobutylmethylxanthine forskolin inhibited rises in [Ca2+]i evoked by thrombin and platelet-activating factor (PAF) due to both Ca2+ influx and release from internal stores with similar potency. Colforsin 52-61 coagulation factor II, thrombin Homo sapiens 99-107 2943273-5 1986 cAMP elevating agents prostaglandin E1 (PGE1) and forskolin had no influence per se on Ca2+-ATPase, but antagonized the inhibitory effect of thrombin. Colforsin 50-59 coagulation factor II, thrombin Homo sapiens 141-149 6088107-4 1983 Forskolin also inhibits the changes in protein phosphorylation pattern induced by the powerful platelet secretagogue, thrombin. Colforsin 0-9 coagulation factor II, thrombin Homo sapiens 118-126 6091624-0 1984 Effects of prostaglandin I2 and forskolin on the secretion from platelets evoked at basal concentrations of cytoplasmic free calcium by thrombin, collagen, phorbol ester and exogenous diacylglycerol. Colforsin 32-41 coagulation factor II, thrombin Homo sapiens 136-144 6091624-3 1984 This secretion evoked by thrombin could be totally suppressed by prostaglandin I2 or forskolin, as expected from the known ability of cyclic AMP to inhibit phospholipase C. The secretory response evoked by collagen at basal [Ca2+]i and that evoked by exogenous diacylglycerol or phorbol ester, direct activators of protein kinase-C, were much less affected by these inhibitors, suggesting that thrombin and collagen may promote formation of diacylglycerol by different mechanisms. Colforsin 85-94 coagulation factor II, thrombin Homo sapiens 25-33 6091624-3 1984 This secretion evoked by thrombin could be totally suppressed by prostaglandin I2 or forskolin, as expected from the known ability of cyclic AMP to inhibit phospholipase C. The secretory response evoked by collagen at basal [Ca2+]i and that evoked by exogenous diacylglycerol or phorbol ester, direct activators of protein kinase-C, were much less affected by these inhibitors, suggesting that thrombin and collagen may promote formation of diacylglycerol by different mechanisms. Colforsin 85-94 coagulation factor II, thrombin Homo sapiens 394-402 6091292-0 1984 Effects of dibutyryl cyclic AMP and forskolin on phospholipid biosynthesis in thrombin-stimulated human platelets. Colforsin 36-45 coagulation factor II, thrombin Homo sapiens 78-86 6091292-3 1984 Pretreatment with forskolin, which increased cellular cAMP content, also resulted in an increase in thrombin-stimulated [3H]glycerol incorporation into phospholipids. Colforsin 18-27 coagulation factor II, thrombin Homo sapiens 100-108 6329175-2 1984 Stimulators of adenylate cyclase (i.e. PGI2, PGD2, forskolin) suppressed or reversed the increase of [Ca2+]i. Inhibitors of adenylate cyclase (i.e. epinephrine, ADP), added before or after thrombin, counteracted PGI2, PGD2 and forskolin and thereby increased [Ca2+]i and restored secretion. Colforsin 51-60 coagulation factor II, thrombin Homo sapiens 189-197 6571835-0 1983 Reversal of thrombin-induced myosin phosphorylation and the assembly of cytoskeletal structures in platelets by the adenylate cyclase stimulants prostaglandin D2 and forskolin. Colforsin 166-175 coagulation factor II, thrombin Homo sapiens 12-20 6571835-6 1983 Increasing thrombin from 0.1 to 1.0 unit/ml inhibited all the responses to PGD2 and forskolin possibly due to concentration-dependent effects of thrombin that inhibit adenylate cyclase. Colforsin 84-93 coagulation factor II, thrombin Homo sapiens 11-19 6571835-6 1983 Increasing thrombin from 0.1 to 1.0 unit/ml inhibited all the responses to PGD2 and forskolin possibly due to concentration-dependent effects of thrombin that inhibit adenylate cyclase. Colforsin 84-93 coagulation factor II, thrombin Homo sapiens 145-153 32552955-4 2020 RESULTS: Compared with the controls, 5 mumol/L forskolin significantly inhibited ADP and collagen-induced platelet aggregation (P<0.001), and showed mild inhibiting effect on Thrombin-induced platelet aggregation (P<0.05). Colforsin 47-56 coagulation factor II, thrombin Homo sapiens 175-183 20202976-12 2010 FSK blunted thrombin-induced CPI-17 phosphorylation, CPI-17/PP1 complex formation, and PP1 inactivation. Colforsin 0-3 coagulation factor II, thrombin Homo sapiens 12-20 18569866-5 2008 We found that both PGE(1) and forskolin inhibited thrombin-induced PLD activation by 40-50%, but interestingly PGE(1) caused a modest elevation of PLD activity in resting platelets. Colforsin 30-39 coagulation factor II, thrombin Homo sapiens 50-58 18569866-7 2008 We found that PGE(1), forskolin and the PKA activator inhibited PLD1 translocation in thrombin-stimulated platelets, and that the PKG-activator had no effect. Colforsin 22-31 coagulation factor II, thrombin Homo sapiens 86-94 19268649-4 2009 Pretreatment of platelets with cAMP-elevating agent, forskolin, abolished thrombin plus collagen-induced MP formation and PS exposure, and obviously decreased calcium ionophore-evoked MP shedding. Colforsin 53-62 coagulation factor II, thrombin Homo sapiens 74-82 19268649-6 2009 PKA inhibitor-induced MP formation was dose-dependently inhibited by calpain inhibitor MDL28170, and forskolin abrogated thrombin plus collagen-induced calpain activation. Colforsin 101-110 coagulation factor II, thrombin Homo sapiens 121-129 18586956-8 2008 Activation of cAMP/PKA cascade by forskolin, which has a barrier-protective effect against thrombin-induced EC permeability, attenuates thrombin-induced phosphorylation of moesin at the cell periphery of control siRNA-treated EC. Colforsin 34-43 coagulation factor II, thrombin Homo sapiens 91-99 18586956-8 2008 Activation of cAMP/PKA cascade by forskolin, which has a barrier-protective effect against thrombin-induced EC permeability, attenuates thrombin-induced phosphorylation of moesin at the cell periphery of control siRNA-treated EC. Colforsin 34-43 coagulation factor II, thrombin Homo sapiens 136-144